Personalis Inc. logo

Personalis Inc.

PSNL | NASDAQ
Chart Builder DCF Calculator
$16.24
-$0.16 (-0.98%)
At close: Sep 21, 2026, 4:00 PM ET
$16.24
$0 (0.00%)
After-hours: Sep 21, 2026, 7:30 PM ET
-0.98%

Rating

Updated: Aug 13, 2026
24.7
Fundamentals Weak
Market Sentiment Bullish
Moat None

Key Statistics

Market Data

Market Cap $1.73B
1D Range
16.07 16.30
52W Range
4.96 18.89

Valuation (TTM)

PE -14.90
PB 7.37
EV/EBITDA -16.04

Valuation (NTM)

Forward PE N/A
Forward PEG 1.16
Price Target $14.95
Loading financial charts...

Profile

Personalis, Inc. operates globally as a specialized cancer genomics firm. The company delivers advanced sequencing and data analysis capabilities, primarily supporting the development of novel cancer ...

Sector Healthcare
Employees 260
IPO Date Jun 19, 2019
Fiscal Year January - December

Latest News

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX)

13 days ago · globenewswire.com

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX)
Personalis, Inc. (NASDAQ:PSNL) Given Consensus Recommendation of “Hold” by Brokerages

20 days ago · defenseworld.net

Personalis, Inc. (NASDAQ:PSNL) Given Consensus Recommendation of “Hold” by Brokerages
Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates

2 months ago · zacks.com

Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates
PSNL Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Personalis to Tempus AI

2 months ago · globenewswire.com

PSNL Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Personalis to Tempus AI
PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie & Holleman Regarding Proposed Sale to Tempus

2 months ago · globenewswire.com

PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie & Holleman Regarding Proposed Sale to Tempus
Personalis Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Personalis, Inc. - PSNL

2 months ago · businesswire.com

Personalis Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Personalis, Inc. - PSNL
Are PSNL, LXP, DSGR, ATAI Obtaining Fair Deals for their Shareholders?

2 months ago · prnewswire.com

Are PSNL, LXP, DSGR, ATAI Obtaining Fair Deals for their Shareholders?
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Personalis, Inc. (NASDAQ: PSNL)

2 months ago · prnewswire.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Personalis, Inc. (NASDAQ: PSNL)
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasdaq – NUVL)

2 months ago · globenewswire.com

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasdaq – NUVL)
Personalis, Inc. (PSNL) M&A Call Transcript

2 months ago · seekingalpha.com

Personalis, Inc. (PSNL) M&A Call Transcript

Earnings

Next Earnings
Nov 3, 2026
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
6
Consensus
Buy
Price Target
$16.25
Upside
+0.06%
Buy (3)
Hold (2)
Sell (0)
Analyst Details

© 2026 bestshares.com. All rights reserved.